site stats

Sideris pharmaceuticals

WebNov 28, 2014 · Most recent fund: $670 million MDV IX fund, first closed 2007 at $580 million. (1) Current biopharma portfolio companies: Adamas, Balance Therapeutics, CardioDx, Crescendo Bioscience, DVS Sciences ... WebSP-420 is covered by an issued patent that has been exclusively licensed to Sideris. Sideris Pharmaceuticals Inc. is a privately held biopharmaceutical company focused on the development of therapeutics for the treatment of transfusion-related iron overload. The company’s operations include facilities in Boston, MA, and in Gainesville, FL.

GT Biopharma Announces Dr. Greg Berk, M.D. Joins Board of …

WebOct 22, 2013 · Sideris Pharmaceuticals's latest funding round was a Series A for $32M on October 22, 2013. Sideris Pharmaceuticals's latest post-money valuation is from October 2013. Sign up for a free trial to see Sideris Pharmaceuticals's valuations in … WebEdimer Pharmaceuticals is dedicated to developing EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare orphan disease that causes a range of symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. Year invested 2013. Investment Stage Early. Sectors. rebecca and rifka https://gmaaa.net

Sideris Pharmaceuticals Careers Wellfound (formerly AngelList …

WebMar 9, 2024 · Allorion has a total of 53 full-time employees in China and the U.S., including 15 executive team members with an average of 15 years of experience in top pharmaceutical and/or biotech companies. The Scientific Advisory Board (SAB) is composed of professors and clinical KOLs that are internationally renowned in the fields … WebOct 23, 2013 · Alongside the equity financing, Sideris entered into an agreement with Novartis Pharmaceuticals whereby Novartis has been granted an exclusive right to acquire Sideris and its lead asset, the iron-chelating candidate SP-420. Including upfront, acquisition and milestone payments, the agreement with Novartis could reach up to $300M. WebSideris Unknown n/a Sideris Pharmaceuticals, Inc. is an independent biopharmaceutical company developing treatments for diseases of iron overload, including conditions involving maintenance transfusion therapy. Sideris’ lead clinical candidate, SP-420, has the potential to be the best-in-class therapeutic approach as an oral iron chelator. university of minho address

News & Media - GT Biopharma

Category:Edimer Pharmaceuticals NEA New Enterprise Associates

Tags:Sideris pharmaceuticals

Sideris pharmaceuticals

Sideris Pharmaceuticals - Products, Competitors, Financials, …

WebSideris Pet Pharmaceuticals. Jan 2024 - Present1 year 10 months. Athens, Attiki, Greece. Development of an OTC patent product for the pet … WebJulio Vega represents public and private companies in a broad range of industries, including biotechnology, medical devices, nanotechnology, advanced materials, software, networking, e-commerce, and fintech. Julio has experience counseling clients on venture capital and other private equity financing transactions, public offerings, mergers and ...

Sideris pharmaceuticals

Did you know?

WebAbfero Pharmaceuticals Inc. is a clinical stage pharmaceutical company focused exclusively on iron as a therapeutic target. Our mission is to develop best-in-class oral iron chelators for the treatment of diseases of iron overload. Patients with systemic iron overload due to transfusions or genetic conditions are at risk for severe organ damage ... WebFounder - CEO at Sideris Pet Pharmaceuticals CEO at Select Software & Business Solutions S.A. CEO at Eurosoft S.A. Greece. Sideris Pet Pharmaceuticals, +5 more. University of Houston, +1 more.

WebFunding. Sideris Pharmaceuticals has raised a total of $32.6M in funding over 2 rounds. Their latest funding was raised on Oct 22, 2013 from a Series A round. Sideris Pharmaceuticals is funded by 3 investors. OUP (Osage University Partners) and Hatteras Venture Partners are the most recent investors. WebMake a donation > GET INVOLVED Services Clinical Research Services SICRES offers a full spectrum of clinical research services to bring about new and innovative solution and findings. Our services cover the entire clinical research and development that can be tailored to national and international trials. Feasibility-2 Feasibility Studies Support the …

WebJan 7, 2014 · Sideris Pharmaceuticals, Inc., is a privately held biopharmaceutical company focused on the development of therapeutics for the treatment of transfusion-related iron overload. WebOct 28, 2013 · Novartis has signed a pact giving it the exclusive right to acquire Sideris Pharmaceuticals, a University of Florida spin-off, for up to $300 million. The deal is a companion to a $32 million fund ...

WebDec 25, 2024 · The urgent need to study and tackle the COVID-19 pandemic also greatly boosted virology research in Greece, with groups from the field and from other disciplines joined their efforts to focus on analyzing molecular, clinical, and epidemiological aspects of SARS-CoV-2 [].Such efforts further enhanced virology research in Greece, increasing the …

WebBerk was President, Chief Medical Officer, and Board Member of Sideris Pharmaceuticals. From May 2012 until January 2014, Dr. Berk was Chief Medical Officer of BIND Therapeutics. Previously, Dr. Berk was Chief Medical Officer at Intellikine, a privately held biotechnology company focused on the discovery and development of novel PI3 Kinase and mTOR … university of minho jobsWebSideris Pharmaceuticals is focused on the development of therapeutics for the treatment of transfusion-related iron overload. Its lead drugs is SP-420, active small molecule that selectively binds iron and removes it from the body. university of mines tarkwa ghanaWebSideris Pharmaceuticals is a biopharmaceutical company that develops therapeutics for the treatment of transfusion-related iron overload. Use the CB Insights Platform to explore Sideris Pharmaceuticals's full profile. university of minho phoneWebExplore {Sideris Pharmaceuticals's key management people. Discover current leadership team members including founders, CEO, other executives and board directors. Sideris Pharmaceuticals CEO, Founder, Key Executive Team, Board of Directors & Employees rebecca and rifka handbagsWebCompany profile page for Sideris Pharmaceuticals Inc including stock price, company news, press releases, executives, board members, and contact information university of minho phd in managementWebHe has 30+ years of experience and has served as President of R&D and CMO of GT Biopharma, CMO of Celularity, executive roles at Verastem, Sideris Pharmaceuticals, BIND Therapeutics, Abraxis BioScience, Intellikine, and served on the integration leadership team during the Celgene acquisition of Abraxis in 2010. university of miniaWebMedtech Insight is part of Pharma Intelligence UK Limited. This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. rebecca and rifka wallet